Overview of BioBank Japan follow-up data in 32 diseases

BioBank Japan Cooperative Hospital Group

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).

Original languageEnglish
Pages (from-to)S22-S28
JournalJournal of epidemiology
Volume27
Issue number3
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Japan
Survival Rate
Survival Analysis
Survival
Cause of Death
Dyslipidemias
Pancreatic Neoplasms
Age Groups
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Epidemiology

Cite this

BioBank Japan Cooperative Hospital Group. / Overview of BioBank Japan follow-up data in 32 diseases. In: Journal of epidemiology. 2017 ; Vol. 27, No. 3. pp. S22-S28.
@article{0b664688d4794cb98235f07981917ed8,
title = "Overview of BioBank Japan follow-up data in 32 diseases",
abstract = "Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48{\%} male) with 1,087,434 person-years and a 97.0{\%} follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).",
author = "{BioBank Japan Cooperative Hospital Group} and Makoto Hirata and Akiko Nagai and Yoichiro Kamatani and Toshiharu Ninomiya and Akiko Tamakoshi and Zentaro Yamagata and Michiaki Kubo and Kaori Muto and Yutaka Kiyohara and Taisei Mushiroda and Yoshinori Murakami and Koichiro Yuji and Yoichi Furukawa and Michiaki Kubo and Toshihiro Tanaka and Yozo Ohnishi and Yusuke Nakamura and Koichi Matsuda and Masaki Shiono and Kazuo Misumi and Reiji Kaieda and Hiromasa Harada and Shiro Minami and Atsushi Watanabe and Naoya Emoto and Kazuhisa Takahashi and Satoru Takeda and Toshinari Funaki and Satoshi Asai and Mitsuhiko Moriyama and Yasuo Takahashi and Tomoaki Fujioka and Wataru Obara and Seijiro Mori and Hideki Ito and Satoshi Nagayama and Yoshio Miki and Akihide Masumoto and Akira Yamada and Yasuko Nishizawa and Ken Kodama and Hiromu Kutsumi and Yoshihisa Sugimoto and Yukihiro Koretsune and Hideo Kusuoka and Kozo Yoshimori",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.je.2016.12.006",
language = "English",
volume = "27",
pages = "S22--S28",
journal = "Journal of Epidemiology",
issn = "0917-5040",
publisher = "Japan Epidemiology Association",
number = "3",

}

BioBank Japan Cooperative Hospital Group 2017, 'Overview of BioBank Japan follow-up data in 32 diseases', Journal of epidemiology, vol. 27, no. 3, pp. S22-S28. https://doi.org/10.1016/j.je.2016.12.006

Overview of BioBank Japan follow-up data in 32 diseases. / BioBank Japan Cooperative Hospital Group.

In: Journal of epidemiology, Vol. 27, No. 3, 01.01.2017, p. S22-S28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overview of BioBank Japan follow-up data in 32 diseases

AU - BioBank Japan Cooperative Hospital Group

AU - Hirata, Makoto

AU - Nagai, Akiko

AU - Kamatani, Yoichiro

AU - Ninomiya, Toshiharu

AU - Tamakoshi, Akiko

AU - Yamagata, Zentaro

AU - Kubo, Michiaki

AU - Muto, Kaori

AU - Kiyohara, Yutaka

AU - Mushiroda, Taisei

AU - Murakami, Yoshinori

AU - Yuji, Koichiro

AU - Furukawa, Yoichi

AU - Kubo, Michiaki

AU - Tanaka, Toshihiro

AU - Ohnishi, Yozo

AU - Nakamura, Yusuke

AU - Matsuda, Koichi

AU - Shiono, Masaki

AU - Misumi, Kazuo

AU - Kaieda, Reiji

AU - Harada, Hiromasa

AU - Minami, Shiro

AU - Watanabe, Atsushi

AU - Emoto, Naoya

AU - Takahashi, Kazuhisa

AU - Takeda, Satoru

AU - Funaki, Toshinari

AU - Asai, Satoshi

AU - Moriyama, Mitsuhiko

AU - Takahashi, Yasuo

AU - Fujioka, Tomoaki

AU - Obara, Wataru

AU - Mori, Seijiro

AU - Ito, Hideki

AU - Nagayama, Satoshi

AU - Miki, Yoshio

AU - Masumoto, Akihide

AU - Yamada, Akira

AU - Nishizawa, Yasuko

AU - Kodama, Ken

AU - Kutsumi, Hiromu

AU - Sugimoto, Yoshihisa

AU - Koretsune, Yukihiro

AU - Kusuoka, Hideo

AU - Yoshimori, Kozo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).

AB - Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).

UR - http://www.scopus.com/inward/record.url?scp=85016390491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016390491&partnerID=8YFLogxK

U2 - 10.1016/j.je.2016.12.006

DO - 10.1016/j.je.2016.12.006

M3 - Article

VL - 27

SP - S22-S28

JO - Journal of Epidemiology

JF - Journal of Epidemiology

SN - 0917-5040

IS - 3

ER -